Abstract：Objective: To explore the value of human papillomavirus (HPV) genotyping and Thin-Cytologic Test (TCT) in screening cervical lesions. Methods: A total of 984 females with regular sexual life who were treated and completed HPV DNA and TCT screening at the outpatient clinic of the hospital between January and October 2019 were selected as the research subjects. Females with HPV positive and TCT ≥ atypical squamous cells with unclear significance (ASC- US) or HPV negative but TCT ≥ low degree squamous intraepithelial lesion (LSIL) underwent colposcopy biopsy. Pathology was taken as the golden standard to evaluate the value of HPV DNA, TCT and their combined screening in diagnosis of cervical lesions. Results: A total of 252 cases of HPV infections were detected in 984 subjects, with an infection rate of 25.61%. The top five HPV infection subtypes were HPV 16 (35.32%), HPV 52 (25.79%), HPV 58 (19.44%) , HPV 18 (9.52%) and HPV 11 (7.94%). Among them, there were 208 cases (82.54%) with single infection and 44 cases (17.46%) with multiple infections. 78 cases were positive for TCT, with a positive rate of 7.93%. Colposcopy and pathological biopsy confirmed 53 cases (67.95%) of abnormalities, including 33 cases of CIN grade 1, 8 cases of CIN grade 2, 7 cases of CIN grade 3, and 5 cases of cervical cancer. The coincidence rate of TCT screening results and pathological examination (52.83%) was lower than HPV (81.13%) and TCT combined with HPV screening (86.79%) (P<0.05). There was no statistically significant difference in the coincidence rate with pathology between TCT combined with HPV screening and single HPV screening (P>0.05). Conclusion: Compared with pathological results, the overall coincidence rate of HPV DNA combined with TCT screening for precancerous cervical lesions and cervical cancer is higher than that of TCT or HPV, which can make up for the defects of TCT screening alone. However, advantages of combined screening with TCT are not significant, compared with HPV screening alone.
姚小艳, 周芳芳, 马为为. HPV基因分型联合TCT筛查宫颈病变的价值分析[J]. 河北医学, 2021, 27(2): 222-227.
YAO Xiaoyan, ZHOU Fangfang, MA Weiwei. Value of HPV Genotyping Combined with TCT in Screening of Cervical Lesions. HeBei Med, 2021, 27(2): 222-227.
[1] Macdonald M,Crossley J,Ellis K,et al. Prevalence of high-grade cervical intraepithelial neoplasia in women with persistent high-risk HPV genotypes and negative cytology[J]. Cytopathology,2018,29(2):133~142. [2] Lam J U H,ElfstromK M,Ejegod D M,et al. High-grade cervical intraepithelial neoplasia in human papillomavirus self-sampling of screening non-attenders[J]. Br Cancer,2018,118(1):138~144. [3] 韩灵云,张芳,马慧敏,等.HPV分型+液基细胞学联合检测与单纯HPV分型检测在宫颈癌及癌前病变筛查中诊断效能比较[J].宁夏医科大学学报,2019,41(11):1149~1152. [4] 闫琼琼,王晓娟.TCT、HPV联合阴道镜在宫颈癌前病变筛查中的应用价值[J].实用癌症杂志,2019,34(7):1104~1106. [5] 高华玲,尹德娥,杜杰,等.TCT和HR-HPV-DNA检测在宫颈癌和癌前病变筛查中的临床价值[J].标记免疫分析与临床,2017,24(10):1115~1118. [6] Clifford G M,Stephen T,Silvia F . Carcinogenicity of human papillomavirus (HPV) types in HIV-positive women:a meta-analysis from HPV infection to cervical cancer[J]. Clin Infect Dis,2017,64(9):1228~1235. [7] Massad L S,Collins Y C,Meyer P M . Biopsy correlates of abnormal cervical cytology classified using the bethesda system[J]. Gynecol Oncol,2001,82(3):516~522. [8] Hoffman S R,Le T,Lockhart A,et al. Patterns of persistent HPV infection after treatment for cervical intraepithelial neoplasia (CIN):a systematic review[J]. Int Cancer,2017,141(1):8~23. [9] Harper D M,Nieminen P,Donders G,et al. The efficacy and safety of tipapkinogen sovacivec therapeutic HPV vaccine in cervical intraepithelial neoplasia grades 2 and 3:randomized controlled phase II trial with 2.5 years of follow-up.[J]. Gynecol Oncol,2019,153(3):521~529. [10] 李丽娟,张秋菊,樊素珍.TCT联合HR-HPV检测在宫颈癌及癌前病变早期筛查中的应用价值[J].癌症进展,2019,17(21):2569~2571. [11] 师晓艳,雷侠.宫颈液基细胞学检查与高危型HPV检测用于宫颈癌前病变并发感染早期筛查的对比研究[J].中国性科学,2017,26(1):33~35. [12] 尤小燕,王雅莉,刘文枝,等.高危型HPV联合细胞学检测在宫颈癌及癌前病变筛查中临床意义[J].实用预防医学,2017,24(8):986~988. [13] Xi L F,Schiffman M,Ke Y,et al. Type-dependent association between risk of cervical intraepithelial neoplasia and viral load of oncogenic human papillomavirus types other than types 16 and 18[J]. Int Cancer,2017,140(8):1747~1756. [14] Tewari D,Novak-Weekley S,Hong C,et al. Performance of the cobas HPV test for the triage of atypical squamous cells of undetermined significance cytology in cervical specimens collected in surePath[J]. Am Clin Pathol,2017,148(5):450~457. [15] 王美英,李芬,杜希林,等.高危型HPVDNA联合TCT检测在宫颈癌初筛中的应用价值[J].国际检验医学杂志,2017,38(5):620~621.
2021, Vol. 27 
冀公网安备13080202000677号